Human epidermal growth factor-functionalized cocoon silk with improved cell proliferation activity for the fabrication of wound dressings

2021 ◽  
pp. 088532822199798
Author(s):  
Meiyu Wu ◽  
Shenyu Huang ◽  
Xiaogang Ye ◽  
Jinghua Ruan ◽  
Shuo Zhao ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Fiber Surface ◽  
Cost Effective ◽  
Wound Dressings ◽  
Wild Type ◽  
Transgenic Silkworm ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

Human epidermal growth factor (hEGF) is a key factor involved in wound healing owing to its powerful ability to stimulate cell proliferation. In this study, we used piggyBac transposon technology to produce transgenic silkworms expressing the hEGF protein fused to truncated heavy chain (FibH-hEGF). The FibH–hEGF fusion protein was successfully expressed and secreted into silkworm cocoons. Compared to wild-type silk, the transgenic silkworm silk had the similar morphology about silks fiber surface and cocoon nets, while the secondary structure between the transgenic silk and wild-type silk was different. Most importantly, transgenic silkworm cocoon silk powder extract significantly increased human fibroblast FIB cell proliferation for a long duration with no apparent cytotoxicity. Our study provides a promising method for obtaining cost-effective and functional biomaterials for the fabrication of wound dressings.

Size effect of human epidermal growth factor-conjugated polystyrene particles on cell proliferation

2020 ◽  
Vol 8 (17) ◽  
pp. 4832-4840
Author(s):  
Setayesh Yasami-Khiabani ◽  
Akbar Karkhaneh ◽  
Mohammad Ali Shokrgozar ◽  
Amir Amanzadeh ◽  
Majid Golkar
Keyword(s):  
Cell Proliferation ◽  
Growth Factors ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Size Effect ◽  
Human Epidermal Growth Factor ◽  
Therapeutic Molecules ◽  
Epidermal Growth

Conjugation of growth factors to a carrier is a favorable method to improve their efficacy as therapeutic molecules.

scholarly journals Cellular Hyperplasia in Rats Following Continuous Intravenous Infusion of Recombinant Human Epidermal Growth Factor

1996 ◽  
Vol 33 (2) ◽  
pp. 184-194 ◽  
Author(s):  
M. A. Breider ◽  
M. R. Bleavins ◽  
J. F. Reindel ◽  
A. W. Gough ◽  
F. A. de la Iglesia
Keyword(s):  
Cell Proliferation ◽  
Amino Acid ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Intravenous Infusion ◽  
Wistar Rats ◽  
Mesenchymal Cell ◽  
Continuous Intravenous Infusion ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

In this study, we determined in vivo morphologic effects of continuous intravenous infusion of recombinant human epidermal growth factor (EGF) in adult Wistar rats. The EGF used consisted of the amino acid residues 1-48 of the human 53-amino-acid EGF molecule, purified from transfected Escherichia coli. Doses of 25, 100, or 250 μg/kg body weight were administered using Harvard digital syringe infusion pumps for 4 weeks. At necropsy, the submandibular salivary glands, Harderian glands, liver, kidneys (females only), and ovaries were enlarged and urinary bladders were thickened in 100- and 250-μg/kg rats. Numerous tissues of the 100- and 250-μg/kg rats contained hyperplastic epithelial cells, and selected organs also had mesenchymal cell proliferation. Epithelial proliferation was most pronounced in the trachea, nasal cavity, nasolacrimal duct, tongue, stomach, small intestine, large intestine, urinary tract, salivary gland ducts, and Harderian gland. Periportal hepatocytes were hypertrophic, correlating with increased liver weight. In addition, mesenchymal cell proliferation was evident in the gastric mucosa lamina propria and in heart valves in 100- and 250-μg/kg rats. Increased ovarian weight correlated with increased number and size of corpora lutea and an increased incidence of luteal cysts. Continuous systemic exposure of adult Wistar rats to high doses of EGF resulted in generalized epithelial hyperplasia and tissue-selective mesenchymal proliferation.

scholarly journals Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

2012 ◽  
Vol 30 (27) ◽  
pp. 3337-3344 ◽  
Author(s):  
Suresh S. Ramalingam ◽  
Fiona Blackhall ◽  
Maciej Krzakowski ◽  
Carlos H. Barrios ◽  
Keunchil Park ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Wild Type ◽  
Small Cell Lung ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non–small-cell lung cancer (NSCLC). Patients and Methods Patients with NSCLC, Eastern Cooperative Oncology Group performance status 0 to 2, no prior HER-directed therapy, and one/two prior chemotherapy regimens received dacomitinib 45 mg or erlotinib 150 mg once daily. Results One hundred eighty-eight patients were randomly assigned. Treatment arms were balanced for most clinical and molecular characteristics. Median progression-free survival (PFS; primary end point) was 2.86 months for patients treated with dacomitinib and 1.91 months for patients treated with erlotinib (hazard ratio [HR] = 0.66; 95% CI, 0.47 to 0.91; two-sided P = .012); in patients with KRAS wild-type tumors, median PFS was 3.71 months for patients treated with dacomitinib and 1.91 months for patients treated with erlotinib (HR = 0.55; 95% CI, 0.35 to 0.85; two-sided P = .006); and in patients with KRAS wild-type/EGFR wild-type tumors, median PFS was 2.21 months for patients treated with dacomitinib and 1.84 months for patients treated with erlotinib (HR = 0.61; 95% CI, 0.37 to 0.99; two-sided P = .043). Median overall survival was 9.53 months for patients treated with dacomitinib and 7.44 months for patients treated with erlotinib (HR = 0.80; 95% CI, 0.56 to 1.13; two-sided P = .205). Adverse event-related discontinuations were uncommon in both arms. Common treatment-related adverse events were dermatologic and gastrointestinal, predominantly grade 1 to 2, and more frequent with dacomitinib. Conclusion Dacomitinib demonstrated significantly improved PFS versus erlotinib, with acceptable toxicity. PFS benefit was observed in most clinical and molecular subsets, notably KRAS wild-type/EGFR any status, KRAS wild-type/EGFR wild-type, and EGFR mutants.

Quantitatively Mapping the Interaction of HER2 and EGFR on Cell Membranes with Peptide Probes

Nanoscale ◽  
2021 ◽  
Author(s):  
Qiuyan Yan ◽  
Mingjun Cai ◽  
Yingying Jing ◽  
Hongru Li ◽  
Haijiao Xu ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Biological Processes ◽  
Her Family ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth ◽  
Peptide Probes

Human epidermal growth factor receptor-2 (HER2) is a member of the epidermal growth factor receptor (HER) family that involved in various biological processes such as cell proliferation, survival, differentiation, migration...

scholarly journals Incorporation of Wild-Type and C-Terminally Truncated Human Epidermal Growth Factor Receptor into Human Immunodeficiency Virus-Like Particles: Insight into the Processes Governing Glycoprotein Incorporation into Retroviral Particles

1999 ◽  
Vol 73 (11) ◽  
pp. 9294-9302 ◽  
Author(s):  
Peter Henriksson ◽  
Tanya Pfeiffer ◽  
Hanswalter Zentgraf ◽  
Alexandra Alke ◽  
Valerie Bosch
Keyword(s):  
Human Immunodeficiency Virus ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Surface Glycoprotein ◽  
Wild Type ◽  
Human Epidermal Growth Factor ◽  
Immunodeficiency Virus ◽  
Epidermal Growth

ABSTRACT Previous results have indicated that incorporation of surface glycoprotein into retroviral particles is not a specific process and that many heterologous viral and cellular glycoproteins can be incorporated as long as they do not have long cytoplasmic C-terminal regions which were presumed to be sterically inhibitory. In this study, this concept has been directly examined by analyzing the incorporation of the wild-type human epidermal growth factor receptor (Wt-EGFR) and of a C-terminally truncated mutant of Wt-EGFR (Tr-EGFR) into human immunodeficiency virus (HIV)-like particles. Incorporation was directly analyzed at the protein level and by immunogold labelling of enriched HIV-like particles. In agreement with the above concept, Tr-EGFR, with only 7 C-terminal amino acids (aa), was efficiently incorporated into HIV-like particles. Incorporation of the Wt-EGFR species, with 542 C-terminal cytoplasmic aa, was reduced by a factor of about 5 in comparison to that of the Tr-EGFR species. However, the Wt-EGFR species was still very significantly present in the HIV-like particles. A series of control experiments verified that this represents genuine incorporation of Wt-EGFR into the membrane of HIV-like particles. These observations allow further speculation as to the processes governing glycoprotein incorporation into retroviral particles and indicate that the internal virus structure of HIV (in particular the matrix layer [MA]) can accommodate much larger heterologous cytoplasmic domains in incorporated glycoproteins than previously assumed.

Sign in / Sign up

Export Citation Format

Share Document